<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Wave Life Sciences Ltd — News on 6ix</title>
<link>https://6ix.com/company/wave-life-sciences-ltd</link>
<description>Latest news and press releases for Wave Life Sciences Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/wave-life-sciences-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835da5a78dffbe2df1236b8.webp</url>
<title>Wave Life Sciences Ltd</title>
<link>https://6ix.com/company/wave-life-sciences-ltd</link>
</image>
<item>
<title>Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-reports-first-quarter-2026-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-reports-first-quarter-2026-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
<description>With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without</description>
</item>
<item>
<title>Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-states</guid>
<pubDate>Tue, 21 Apr 2026 20:01:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, is seeking shareholders’ and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”), in order to redomicile the parent company of the Wave Life Sciences grou</description>
</item>
<item>
<title>Wave Life Sciences Announces Proposed Redomiciliation to the United States</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-proposed-redomiciliation-to-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-proposed-redomiciliation-to-the-united-states</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-positive-interim-phase-1-data-from-inlight-further-improvements-in-body-composition-with-clinically-meaningful-reductions-in-visceral-fat-and-waist-circumference-at-six-months-following-single-dose-of-wve-007</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-positive-interim-phase-1-data-from-inlight-further-improvements-in-body-composition-with-clinically-meaningful-reductions-in-visceral-fat-and-waist-circumference-at-six-months-following-single-dose-of-wve-007</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%;</description>
</item>
<item>
<title>Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference-33</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-acceptance-of-late-breaking-oral-presentation-on-wve-006-for-alpha-1-antitrypsin-deficiency-at-the-american-thoracic-society-international-conference-33</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose</description>
</item>
<item>
<title>Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing</description>
</item>
<item>
<title>Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the</description>
</item>
<item>
<title>Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-fourth-quarter-and-full-year-2025-financial-results-scheduled-for-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-fourth-quarter-and-full-year-2025-financial-results-scheduled-for-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the i</description>
</item>
<item>
<title>Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-plans-123000777</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-plans-123000777</guid>
<pubDate>Mon, 02 Feb 2026 12:30:00 GMT</pubDate>
<description>WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026 Data from the 400 mg multidose cohort of RestorAATion-2 clinical trial remain on track for first quarter o</description>
</item>
<item>
<title>Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-highlights-strategic-123000794</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-highlights-strategic-123000794</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026 Initial WVE-007 240 mg single-dose data reported in 2025 demonstrated improved body composition with fat loss similar to GLP-1 at three months with muscle preservation and the potential for once or twice-yearly dosing; higher dose</description>
</item>
<item>
<title>Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-prices-upsized-350-million-public-offering-ordinary-shares-and-pre</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-prices-upsized-350-million-public-offering-ordinary-shares-and-pre</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-proposed-250-million-public-offering-ordinary-shares-and</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-proposed-250-million-public-offering-ordinary-shares-and</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-positive-interim-data-phase-1-inlight-trial-wve-007</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announces-positive-interim-data-phase-1-inlight-trial-wve-007</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4%</description>
</item>
<item>
<title>Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announce-interim-data-phase-1-inlight-trial-wve-007-inhbe-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-announce-interim-data-phase-1-inlight-trial-wve-007-inhbe-obesity</guid>
<pubDate>Sun, 07 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-reports-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-reports-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of</description>
</item>
<item>
<title>Wave Life Sciences to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-present-upcoming-investor-conferences-2025-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-present-upcoming-investor-conferences-2025-11-07</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-present-preclinical-data-supporting-therapeutic-potential-wve-007</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-present-preclinical-data-supporting-therapeutic-potential-wve-007</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity</description>
</item>
<item>
<title>Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-third-quarter-2025-financial-results-scheduled-november-10-2025</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/wave-life-sciences-third-quarter-2025-financial-results-scheduled-november-10-2025</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the</description>
</item>
<item>
<title>Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day</title>
<link>https://6ix.com/company/wave-life-sciences-ltd/news/correcting-and-replacing-wave-life-sciences-announced-positive-target-engagement-data</link>
<guid isPermaLink="true">https://6ix.com/company/wave-life-sciences-ltd/news/correcting-and-replacing-wave-life-sciences-announced-positive-target-engagement-data</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the</description>
</item>
</channel>
</rss>